E-MAIL UPDATES

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Quarterly Activities Report & Appendix 4C

January 22nd 2021
press releases

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 22nd 2021
press releases

Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study

January 7th 2021
press releases
more

Investor updates

Investor updates.

Investor Update - August 2020

August 17th 2020
investor updates

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates
more

Analyst reports

Analyst reports.

goetzpartners securities - Door re-opens to first eftilagimod alpha approval

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

December 14th 2020
analyst reports

Maxim - Efti Was Out in Breast Cancer...Or Was it? Update from Ongoing SABCS meeting, Raising PT to $8

December 10th 2020
analyst reports

Maxim - Collaboration with Merck Expands in 1L Lung Cancer, Expanding to 1L Head & Neck, Equity Financing Complete

November 19th 2020
analyst reports
more